NEW YORK, Oct. 21 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0316091/Indian-Bulk-Drug-Market.html
Indian bulk drug industry to grow to US$ 17 billion by 2014
Indian Bulk Drug industry is expected to grow at a CAGR of 21% to reach US$16.91 billion by 2013-14 as per a Cygnus study. Cygnus estimates the size of Indian bulk drug industry for 2009-10 at US$ 11.54 billion, out of which exports contribute about US$ 7.5 billion, constituting 65% of the industry. Indian Contract Manufacturing market stood at US$986m in 2009 and is expected to grow at a CAGR of 41.7% to reach US$5.63 billion by 2014.
India has the highest number of Drug Master Filings (DMF) amongst all key competing economies. From 2000-2008 India had more than 1614 filings, 3 times higher than that of China. Other Countries such as Italy, Spain, Mexico, Brazil etc are far behind as compare to India. The share of Drug Master Filings made by Indian firms has increased considerably from 14% in 2000 to 50% in 2009.
In view of the significant growth potential of Indian bulk drugs industry, Cygnus releases the latest version of the Indian Bulk Drugs Industry Insight. The report will be useful to senior executives associated with the industry, bankers, private equity players, investors, students, research scholars and industry analysts who need relevant industry inputs for their work.
SCOPE OF THE REPORT
• Global and Indian Bulk Drug Market
• Key Growth Drivers
• Industry Regulations
• Issues & Challenges
• Major Players – Business profile, Their Bulk Actives therapeutic segment wise, Strategies, M& A / Alliances, Financial Profile, SWOT Analysis and Future Outlook.
• Major Medical Institutes
• Critical Success Factors
• Future outlook
HIGHLIGHTS OF THE REPORT
• Major therapeutic categories and Annual Production of Major Bulk Drugs
• Major Deals Announced/Completed By Indian Companies
• Drug Patent Expirations
• ANDA Filings by Indian Companies
• R&D Expenditure
• DMF filings by Indian companies
• India's Advantages for Contract Manufacturing
• A Comparison between India and China
• 320 DMF filings by Indian companies
• List of Bulk Drugs Manufacturers in India
REASONS TO BUY
• Latest and Very Comprehensive report on Indian API Market
• Gives insights into Indian Pharma industry also along with the outsourcing market
• Lists of various sought after Data such as patent expirations, DMF, import - export etc
RELATED REPORTS –
Indian Pharmaceutical Markets, Quarterly Update & Analysis on Indian Pharma, Indian Dental Market, Clinical Trials in India, CRAMS Market
CONTENTS
1. Executive Summary
2. Highlights
3. Global Bulk drugs Market --- Market Overview
3.1. Introduction
3.2 Global Bulk Drugs Market
4. Indian Bulk Drugs Market---- an Overview
4.1 Indian Pharmaceutical Market
4.2 Indian Bulk Drugs
4.3 Growth Trends
4.4 Future outlook
5. Growth Drivers
5.1 High Growth of Generics / Patent expiries
5.2 New Drug Developments
5.3 Contract Manufacturing
5.4 Overall Pharmaceutical Growth
5.5 Reduced Manufacturing cost
6. Industry Regulations
6.1 Budget measures
6.2 Policy changes
6.3 Regulatory Bodies
6.4 Pharmaceutical Policy-2002
6.5 National pharmaceutical policy 2006
6.6 Pricing of Scheduled Bulk Drugs
6.7 Indian Patent law
6.8 Labelling System in India
6.9 Intellectual Property Rights (IPR)
6.10 Trade Related Aspects of Intellectual Property Rights (TRIPS)
6.11 Bulk drugs prices come under NPPA lens
7. Issues & Challenges
7.1 Increasing Competition
7.2 Coping with Changing Disease Profile
7.3 Over Capacity
7.4 Undifferentiated Capabilities
7.5 Varying regulatory requirements lead to additional costs
7.6 Threat from China
8. Major Players
8.1 Aurobindo Pharma
8.2 Ranbaxy Laboratories
8.3 Dr. Reddy's Laboratories
8.4 Lupin Ltd
8.5 Matrix Laboratories
8.6 Cipla Ltd
8.7 Orchid Chemicals and Pharmaceuticals Ltd.
8.8 Divis laboratories
8.9 Sun Pharmaceutical Industries Ltd
8.10 Ipca Laboratories Ltd.
8.11 Dishman Pharmaceutical and Chemicals Ltd
8.12 Cadila Healthcare Ltd
8.13 Alembic Ltd
8.14. Glaxo SmithKline Pharmaceuticals Ltd.
8.15 Glenmark Pharmaceuticals Ltd.
8.16 Piramal Healthcare Limited (PHL)
8.17 Unichem Laboratories Ltd
8.18 Merck India Ltd.
8.19 Atul Ltd
9. Critical Success Factors
9.1 Low-Cost Manufacturing Skills
9.2 Striking Strategic Alliances (Mergers & Acquisitions)
9.3 Growing Experience with cGMP Compliance
9.4 Complex Synthesis Capabilities
9.5 Identifying New Opportunities Holds the Key for Generic Manufacturers
9.6 Indian Companies enter in to Global Cancer Drugs Market
9.7 Focus on New therapeutic Segments
9.8 Time the Market
9.9 Accreditations
10. Future Outlook
Annexure 1: List of Abbreviations
Annexure 2: DMF filings by Indian companies
Annexure 3: List of Bulk Drugs Manufacturers in India
Annexure 4: List of Industry Organizations
Annexure 5: Bibilography
List of Figures
Figure 3.1: Global pharmaceutical market value (2005-2009)
Figure 3.2: Global Market Share in % (2009)
Figure 3.3: Global Bulk Drugs Market Size (2006-10)
Figure 4.1: Indian Domestic Pharmaceutical Market
Figure 4.2: Major Therapeutic Segments as% Contribution (2008-09)
Figure 4.3: Vision 2010: Glimpse of Indian Pharmaceutical Market Future
Figure 4.4: Total Market Size (2004-09)
Figure 4.5: Exports Vs Exports (%) to total
Figure 4.6: Indian bulk drugs Imports
Figure 5.1: Global Contract Manufacturing Market
List of Tables
Table 1: Leading Therapeutic Segments
2009
Table 2: Leading Brands
2009
Table 3: Major Markets
2009
Table 4: Market Segment (US$ bn)
Table 5: Global Major Players Table 6: Major Acquisition in 2005-10
Table 7: Annual Production of Major Bulk Drugs
Table 8: Major Deals Announced/Completed By Indian Companies
Table 9: ANDA Filings by Indian Companies
Table 10: R&D Expenditure
2008-09
Table 11: DMF filings by Indian companies
Table 12: India's Advantages for Contract Manufacturing
Table 13: Comparison between India and China
To order this report:
Drug and Medication Industry: Indian Bulk Drug Market
Drug and Medication Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article